Wegovy vs. Zepbound vs. Saxenda: How These Prescription Weight-Loss Medications Compare

For informational purposes only — not medical advice. Treatment decisions should be made with a licensed healthcare provider.

Prescription weight-loss medications have expanded in recent years. Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) are three widely used prescription brand-name options for chronic weight management in the United States. They are not interchangeable: they differ in mechanism, route and dosing schedule, approved ages and indications, expected weight-loss outcomes, safety warnings, and cost or coverage.

As of March 2026, Wegovy is available in two forms for adults: a once-weekly subcutaneous injection and a once-daily oral tablet. Zepbound remains a once-weekly injection. Saxenda remains a once-daily injection. This is a meaningful practical difference that affects who qualifies for each formulation and how treatment is managed.

All three require a prescription and ongoing medical supervision. All three are supported by clinical trial evidence. The right choice for any individual patient depends on their medical history, goals, insurance coverage, and clinical judgment — not on any general ranking. This guide provides the factual comparison needed to support that conversation with a healthcare provider.

Wegovy vs. Zepbound vs. Saxenda at a Glance

What Is Wegovy?

Wegovy is a semaglutide prescription medication from Novo Nordisk. In the U.S., Wegovy is available as a once-weekly subcutaneous injection and, for adults, as a once-daily oral tablet. The injection is approved for chronic weight management in adults and in adolescents aged 12 and older with obesity; the tablets are approved for adults only.

Wegovy injection also carries FDA-approved indications beyond weight management: it is the only medication among the three with FDA approval to reduce the risk of major adverse cardiovascular events (CV death, non-fatal heart attack, non-fatal stroke) in adults with established cardiovascular disease and overweight or obesity. The injection also holds an accelerated approval indication for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

How Wegovy Works

Wegovy belongs to a class of drugs called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, and — critically for weight management — signals areas of the brain involved in appetite regulation that food intake has occurred. By mimicking GLP-1 at pharmacological levels, Wegovy amplifies and extends these signals beyond what the body produces naturally, resulting in reduced appetite, earlier satiety, and meaningful caloric reduction.

The weekly injection has a half-life of approximately one week, allowing steady-state drug levels with once-weekly dosing. The oral tablet uses a different delivery mechanism (co-formulated with SNAC, an absorption enhancer) and is taken daily on an empty stomach with a small amount of water.

Who May Qualify for Wegovy

The FDA-approved indications for the Wegovy injection in adults are:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, high cholesterol, obstructive sleep apnea, cardiovascular disease, or other), or
• Established cardiovascular disease with overweight or obesity (for CV risk-reduction indication)

For adolescents aged 12 to 17, the Wegovy injection is approved for those with a BMI at or above the 95th percentile for age and sex. Wegovy tablets are not approved for pediatric patients.

Dosing Schedule — Wegovy Injection

The 2.4 mg dose is recommended for most adults; 1.7 mg is also an approved maintenance dose when tolerability warrants it. Titration can be slowed if side effects are difficult to manage.

Dosing Schedule — Wegovy Tablets (Adults Only)

The tablet must be taken on an empty stomach in the morning with up to 4 ounces of water; the patient must wait at least 30 minutes before eating, drinking other beverages, or taking other oral medications. Tablets should be swallowed whole and not split, crushed, or dissolved.

Pros of Wegovy

• Once-weekly injection supports adherence
• Strongest cardiovascular outcomes evidence among the three (SELECT trial, 20% MACE reduction)
• Only drug among the three with an FDA-approved CV risk-reduction indication
• Available as oral tablets — meaningful option for patients who prefer not to inject
• Injection approved for adolescents 12+
• MASH indication (injection only, accelerated approval)
• Large evidence base across multiple STEP trials

Cons of Wegovy

• GI side effects common during titration (nausea 44%, vomiting 24%, diarrhea 30% in adult weight-loss trials)
• Resting heart rate increase documented — labeling requires regular monitoring
• Wegovy tablets not established for pediatric patients or patients with type 2 diabetes (tablets studied primarily in adults without T2DM)
• Cost and access vary by plan and savings program

What Is Zepbound?

Zepbound is manufactured by Eli Lilly and received FDA approval for chronic weight management in adults in November 2023. Its active ingredient is tirzepatide — the same molecule in Mounjaro, which is FDA-approved for type 2 diabetes. For a full comparison of where to get tirzepatide online, see our best tirzepatide online guide.

How Zepbound Works

Zepbound is a GIP and GLP-1 receptor dual agonist, often called a "twincretin." GIP (glucose-dependent insulinotropic polypeptide) is a second gut incretin hormone. GIP receptors are found not only in the pancreas but also in fat tissue and the brain. Activating both GLP-1 and GIP receptors simultaneously appears to produce greater reductions in appetite, caloric intake, and body fat than GLP-1 stimulation alone — reflected in the clinical trial outcomes.

Who May Qualify for Zepbound

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher with at least one weight-related comorbidity

As of March 17, 2026, Zepbound is approved for adults only. It has not received FDA approval for adolescents or pediatric patients. Zepbound also carries FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity.

Dosing Schedule

For weight management, approved maintenance doses are 5 mg, 10 mg, or 15 mg weekly. For OSA, approved maintenance doses are 10 mg or 15 mg weekly. Dose escalation can be slowed based on tolerability. Many patients achieve meaningful results at 5 mg or 10 mg without requiring the maximum dose.

Current U.S. presentations include single-dose pens, single-dose vials, multi-dose vials (4 doses per vial), and the single-patient-use KwikPen (4 doses per pen). If the prescribed presentation changes, patients should receive training appropriate to the new format.

Pros of Zepbound

• Highest average weight-loss outcomes in pivotal clinical trials
• Once-weekly injection
• Lower self-pay price than Wegovy injection at many dose levels
• Additional FDA indication for obstructive sleep apnea
• Multiple presentation options (single-dose pens, vials, KwikPen)

Cons of Zepbound

• Not approved for adolescents under 18
• Does not have an FDA cardiovascular-event-reduction indication as of March 17, 2026
• Gallbladder disease is a recognized risk (cholelithiasis 1.1%, cholecystitis 0.7% in pooled weight-loss trials)
• Hair loss listed as a common adverse reaction in labeling
• Suicidal behavior and ideation warning remains in current labeling (section 5.9); providers should monitor for emergence of depression or suicidal thoughts

What Is Saxenda?

Saxenda is the oldest of the three medications, FDA-approved in December 2014. Also manufactured by Novo Nordisk, its active ingredient is liraglutide. Unlike Wegovy, Saxenda uses a different GLP-1 receptor agonist molecule with a shorter half-life, which requires daily injection.

How Saxenda Works

Like Wegovy, Saxenda is a GLP-1 receptor agonist. It mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and promote satiety. However, liraglutide has a shorter biological half-life (roughly 13 hours) compared to semaglutide's approximately one-week half-life, which is why daily injections are required. The efficacy difference between Saxenda and Wegovy reflects genuine differences in potency and receptor-binding characteristics between liraglutide and semaglutide — not simply a difference in dosing frequency.

Who May Qualify for Saxenda

In adults:

• BMI of 30 or higher, or
• BMI of 27 or higher with at least one weight-related comorbidity

For adolescents aged 12 to 17: body weight greater than 60 kg and obesity (BMI at or above the 95th percentile for age and sex). The safety and effectiveness of Saxenda in pediatric patients with type 2 diabetes have not been established.

Dosing Schedule

Maintenance dose (3.0 mg daily) is typically reached by week 5. For pediatric patients who cannot tolerate 3.0 mg, dose may be reduced to 2.4 mg; dose escalation in pediatric patients may take up to 8 weeks.

Pros of Saxenda

• Longest track record — approved since 2014 with over a decade of real-world data
• Approved for adolescents 12+ (body weight >60 kg)
• May still be covered on insurance plans that don't cover newer agents
• Daily dosing gives patients more flexibility to adjust timing

Cons of Saxenda

• Daily injection — significant adherence burden compared to weekly options
• Lower average weight-loss outcomes than Wegovy or Zepbound
• No cardiovascular or OSA indication for the obesity label
• Injection fatigue more likely over time with daily dosing

Clinical Efficacy: What the Trials Actually Show

The Key Trials

Wegovy (semaglutide): The STEP 1 trial enrolled 1,961 adults without diabetes and found that semaglutide 2.4 mg weekly produced an average body weight reduction of 14.9% over 68 weeks, versus 2.4% with placebo. Approximately 86% of participants achieved at least 5% weight loss; 69% achieved at least 10%; 50% achieved at least 15%.

Zepbound (tirzepatide): SURMOUNT-1 enrolled 2,539 adults without diabetes and showed average weight loss of 15.0% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. At the maximum dose, 91% of participants achieved at least 5% weight loss and 57% achieved at least 20% — a threshold previously linked primarily to bariatric surgery outcomes.

Saxenda (liraglutide): The SCALE Obesity and Pre-diabetes trial showed average weight loss of approximately 8.0–8.4% over 56 weeks versus 2.6% with placebo. Approximately 63% of participants achieved at least 5% weight loss and 33% achieved at least 10%.

Side-by-Side Efficacy

Head-to-Head Evidence

There is no published randomized controlled trial directly comparing all three medications against each other. These numbers come from separate trials with different patient populations and timeframes, making direct comparisons imprecise. Real-world observational studies generally point in the same direction as the pivotal trials — on average, tirzepatide tends to produce more weight loss than semaglutide, and semaglutide more than liraglutide — but these comparisons are less reliable than direct randomized head-to-head trials.

What These Numbers Mean Practically

For a 250-pound person, based on population trial averages:

• Saxenda: approximately 20 lbs
• Wegovy: approximately 37 lbs
• Zepbound (15 mg): approximately 52 lbs

These are averages. Individual responses vary considerably. Some patients lose substantially more than the average; others less. Non-response and plateau periods occur across all three medications.

The Weight Regain Reality

All three medications must typically be continued long-term to maintain results. When discontinued, a substantial portion of lost weight returns — STEP 4 data showed approximately two-thirds of lost weight regained within one year of stopping semaglutide. Similar patterns have been observed with liraglutide and tirzepatide. Providers and patients should plan for long-term use from the outset rather than treating these as short-term interventions.

Side Effects: A Comparison by Drug

All three share a common side-effect profile rooted in GLP-1 receptor activation, which slows gastric emptying and acts on the brainstem's vomiting center. Most side effects peak during dose escalation and improve at steady maintenance dosing.

Common Side Effects Across All Three

Across the three products, common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain or discomfort, and injection-site reactions. Fatigue, headache, dyspepsia, dizziness, and eructation are also reported. These were most frequent during dose escalation in all three trials.

Wegovy-Specific Adverse Reaction Notes

From adult weight-loss trials (Wegovy injection 2.4 mg):

• Nausea: 44% (Wegovy) vs. 16% (placebo)
• Diarrhea: 30% vs. 16%
• Vomiting: 24% vs. 6%
• Constipation: 24% vs. 11%
• Hair loss: 3% vs. 1%

Mean increases in resting heart rate of 1–4 beats per minute were observed in adults. Labeling requires regular heart rate monitoring.

Suicidality warning status: The suicidal behavior and ideation warning was removed from Wegovy's U.S. labeling in February 2026.

Zepbound-Specific Adverse Reaction Notes

In pooled weight-loss trials (SURMOUNT-1 and -2), in addition to shared GI reactions, the Zepbound label specifically lists hair loss, eructation (burping), and gastroesophageal reflux disease among common adverse reactions (≥5%).

In those same trials:

• Cholelithiasis (gallstones): 1.1% of Zepbound-treated patients vs. 1% placebo
• Cholecystitis: 0.7% vs. 0.2%

Suicidality warning status: The suicidal behavior and ideation warning remains in Zepbound's current U.S. labeling (section 5.9) as of January 2026. Providers should monitor for emergence of depression or suicidal thoughts.

Saxenda-Specific Adverse Reaction Notes

Saxenda's daily dosing produces steadier plasma drug levels. For some patients, this means more consistent but potentially lower-intensity GI effects compared to the weekly peaks of Wegovy and Zepbound. Hypoglycemia risk is specifically noted when Saxenda is used with an insulin secretagogue or insulin in adults with type 2 diabetes.

Suicidality warning status: The suicidal behavior and ideation warning was removed from Saxenda's U.S. labeling in February 2026.

Serious Adverse Events: All Three Drugs

Boxed warning (all three): All three medications carry an FDA boxed warning about the risk of thyroid C-cell tumors based on rodent studies. A causal relationship has not been established in humans, but all three are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Pancreatitis: Cases of acute pancreatitis have been reported across all three. Patients with a history of pancreatitis should discuss this risk with their provider before starting any of these medications.

Gallbladder disease:

• Wegovy injection (adult weight-loss trials): cholelithiasis 1.6%, cholecystitis 0.6%
• Zepbound (pooled weight-loss trials): cholelithiasis 1.1%, cholecystitis 0.7%
• Saxenda: gallbladder disease warning is present in labeling; rates are similar in pattern

Rapid weight loss of any cause increases gallstone risk, and GLP-1 receptor activation may affect gallbladder motility. Any new upper-right abdominal pain should be evaluated promptly.

Pulmonary aspiration during anesthesia: Current U.S. labeling for all three medications includes a warning about rare postmarketing reports of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. Patients should inform their surgical and anesthesia teams before any planned procedure.

Formal Contraindications and Important Cautions

Formal Contraindications Shared by All Three

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to the active ingredient or any excipient

Important Warnings and Precautions (Not Formal Contraindications)

Pregnancy: All three medications may cause fetal harm. For Wegovy and Zepbound, when pregnancy is recognized, the labeling advises discontinuation. Weight loss offers no benefit during pregnancy. These medications are not formally contraindicated in pregnancy (pregnancy was removed from the contraindications sections of Saxenda in May 2025 and was never listed as a formal contraindication for Wegovy or Zepbound), but they are not used for weight loss during pregnancy and discontinuation upon confirmed pregnancy is the standard clinical approach.

Reproductive counseling:

• Wegovy: Because of semaglutide's long half-life (~1 week, with the drug present in circulation for approximately 5–7 weeks after the last dose), labeling advises discontinuing Wegovy at least 2 months before a planned pregnancy to account for this washout period.
• Zepbound: Patients using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, because tirzepatide's effect on gastric emptying can transiently reduce oral contraceptive absorption.

Severe gastroparesis: All three medications are not recommended in patients with severe gastroparesis (this is a labeled warning/precaution, not a formal contraindication).

Hepatic and renal impairment: For Wegovy injection and tablets, the labeling indicates no clinically significant pharmacokinetic differences based on hepatic impairment severity. For Saxenda, the labeling lists hepatic impairment under specific population cautions and advises careful monitoring. All three carry warnings about acute kidney injury risk due to volume depletion from GI side effects — hydration monitoring is especially important during dose escalation.

Cost, Insurance, and Affordability

Cost is one of the most decisive real-world factors in which medication a patient ends up on. The landscape has changed substantially since 2024.

Current Self-Pay Pricing (As of Early 2026)

The traditional "list price" framing for these medications has become less meaningful as manufacturers have shifted to consumer-facing self-pay pathways:

• Wegovy: Novo Nordisk's NovoCare program currently advertises self-pay pricing around $349/month for most injection dose strengths, with limited-time introductory offers at lower rates for some new patients. Verify current terms at novocare.com.
• Zepbound: Lilly's self-pay program currently advertises pricing from approximately $299–$449/month depending on dose and program eligibility. Verify current terms at lilly.com or zepbound.com.
• Saxenda: Check Novo Nordisk's current savings program for Saxenda terms.

Insurance Coverage

Commercial insurance (employer-sponsored plans): Coverage varies significantly by employer, plan, and year. Some large employers have added GLP-1 coverage for weight loss; many others have excluded these drugs due to cost. Plans differ in which products are covered, at what tier, and with what prior authorization requirements.

Medicare Part D: Federal law still generally prohibits Medicare Part D coverage for drugs prescribed solely for weight loss. However, Wegovy may be covered by Medicare Part D when prescribed for its FDA-approved cardiovascular risk-reduction indication in eligible patients with established CVD — a meaningful distinction for a large subset of patients. This coverage pathway does not exist for Zepbound or Saxenda, as neither holds an equivalent CV indication.

Medicaid: Coverage is highly variable by state. Check your state's current formulary.

Prior authorization: Even when covered, most insurers require prior authorization with documentation of qualifying BMI, comorbidities, and often prior lifestyle intervention.

Manufacturer Savings Programs

• NovoCare (Wegovy): Commercially insured patients may qualify for significant monthly savings. Income-based assistance is available through Novo Nordisk for uninsured patients.
• Lilly (Zepbound): Commercially insured and self-pay options; Lilly's multi-dose vials and KwikPen also offer lower per-dose costs in some scenarios.
• Saxenda MyWay: Savings program available; check current eligibility terms.

These programs have eligibility restrictions and change over time. Verify current terms directly with manufacturers.

Telehealth and Online Prescribing Platforms

A significant portion of GLP-1 prescriptions are now written through telehealth platforms. If using such a platform, verify that the provider employs licensed prescribers in your state, follows established clinical guidelines, and clearly discloses whether they prescribe FDA-approved brand-name products, compounded products, or both.

A Note on Compounded Semaglutide and Tirzepatide

During the period when FDA-listed drug shortages for semaglutide and tirzepatide were in effect, compounding pharmacies were legally permitted to produce copies. Those shortage designations were removed, and the FDA has since taken enforcement actions against compounders continuing to produce these drugs outside shortage conditions. If you are using or considering compounded GLP-1 products, verify the current regulatory status with your provider.

Wegovy vs. Zepbound: Head-to-Head

Efficacy

Clinical trial data consistently shows higher average weight-loss outcomes with tirzepatide (Zepbound) than semaglutide (Wegovy). These are separate trials with different populations, so the comparison is indirect. Real-world observational evidence generally aligns with this direction, but individual responses vary considerably, and there is no validated biomarker predicting which drug a given patient will respond to better.

Cardiovascular Evidence

This is where Wegovy holds a significant, unique advantage. The SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity (without diabetes) and found that semaglutide 2.4 mg injection reduced the risk of major adverse cardiovascular events by 20% compared to placebo (hazard ratio 0.80, 95% CI 0.72–0.90). This led to Wegovy's expanded FDA label for CV risk reduction.

Zepbound does not have an FDA cardiovascular-event-reduction indication as of March 17, 2026. The SURMOUNT-MMO cardiovascular outcomes trial remains ongoing. For patients with established cardiovascular disease, Wegovy has stronger current regulatory support.

Who Wegovy May Be the Better Fit

• Patients with established cardiovascular disease who want proven CV risk reduction
• Adults who prefer an oral tablet option
• Adolescents aged 12–17 (Zepbound not approved for this group)
• Medicare patients covered under the CV indication pathway
• Patients where insurance covers Wegovy but not Zepbound

Who Zepbound May Be the Better Fit

• Patients prioritizing maximum possible weight-loss outcome
• Patients with concurrent type 2 diabetes (tirzepatide's glucose-lowering adds further metabolic benefit)
• Patients with concurrent obstructive sleep apnea (specific FDA indication)
• Self-pay patients who benefit from Lilly's pricing options

Wegovy vs. Saxenda: Head-to-Head

The Molecular Difference

Both are GLP-1 receptor agonists made by Novo Nordisk, but semaglutide (Wegovy) has a much longer half-life (~1 week) than liraglutide (Saxenda, ~13 hours). This drives the weekly vs. daily dosing difference. Beyond half-life, semaglutide binds the GLP-1 receptor with higher affinity, which is the likely mechanism behind its substantially greater average efficacy.

Efficacy Gap

The ~14.9% average weight loss with Wegovy versus ~8% with Saxenda in their respective pivotal trials is a clinically meaningful difference. For most patients who qualify for both and can access either, clinical evidence favors Wegovy. Because semaglutide produced greater average weight loss in pivotal trials and is dosed weekly instead of daily, many clinicians consider Wegovy the more potent and more convenient option when access and tolerability allow — based on the trial results and dosing schedules, not on a direct head-to-head randomized comparison.

Compliance and Daily Burden

Weekly vs. daily injection has a meaningful real-world impact on adherence. Real-world data on GLP-1 medication persistence consistently shows higher continuation rates with weekly injectables. That said, some patients genuinely prefer daily dosing — more flexible timing, ability to delay a dose without a full week's disruption, or a psychological preference for daily routine. These individual factors matter.

When Saxenda Is Still Prescribed in 2025–2026

• Insurance formularies that cover liraglutide but not semaglutide
• Patients who experienced intolerable side effects on semaglutide
• Adolescents where a provider prefers the daily titration for monitoring purposes
• Situations where Wegovy is locally unavailable

Zepbound vs. Saxenda: Head-to-Head

This comparison has the widest efficacy gap. Zepbound's 20.9% maximum-dose average versus Saxenda's 8% represents more than a twofold difference in average outcomes, and these are mechanistically quite different drugs (dual GLP-1/GIP agonist versus GLP-1 alone). The practical drivers of choosing Saxenda over Zepbound in this pairing are almost exclusively access-related: insurance coverage, formulary restrictions, adolescent patients (Zepbound not approved under 18), or specific tolerance/history considerations.

Special Populations

Patients with Type 2 Diabetes

Important clarification on naming: Ozempic and Wegovy both contain semaglutide; Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly, while Wegovy is approved for weight management at 2.4 mg weekly. Mounjaro and Zepbound both contain tirzepatide; Mounjaro is approved for type 2 diabetes, Zepbound for weight management. Insurance coverage may determine which version a patient can access. This is a common source of confusion that is worth discussing explicitly with your provider.

For patients with both obesity and type 2 diabetes, tirzepatide's dual mechanism has shown strong combined metabolic benefits, including HbA1c reductions of 1.5–2.4 percentage points alongside weight loss. Providers frequently consider tirzepatide in this population. Note that Wegovy tablets have not been studied for weight reduction in adults with type 2 diabetes and obesity; for those patients, the injection formulation is more appropriate.

Cardiovascular Disease Patients

Wegovy is the only medication among the three with Level A cardiovascular outcomes data from a large, dedicated RCT (SELECT). For a patient with established atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral artery disease) who also has overweight or obesity and no diabetes, Wegovy injection is the only one of the three with FDA-approved language for CV risk reduction.

An important Medicare note: this CV indication also provides a pathway for Medicare Part D coverage of Wegovy in eligible patients — a distinction that has major financial implications for this population.

Adolescents (Ages 12–17)

Wegovy injection and Saxenda are both FDA-approved for adolescents 12 and older (Saxenda requires body weight >60 kg). Zepbound is not currently approved in this age group.

The STEP TEENS trial showed an average 16.1% body weight reduction with semaglutide in adolescents — higher than the adult STEP 1 result. These findings have positioned Wegovy injection as the preferred injectable option for adolescent obesity management in current clinical practice.

Prescribing these medications in adolescents is a nuanced decision requiring shared decision-making between the patient, family, and a specialized provider (typically a pediatric endocrinologist or pediatric obesity medicine specialist).

Patients with Obstructive Sleep Apnea

Zepbound is the only medication among the three with an FDA approval specifically for OSA in adults with obesity. The SURMOUNT-OSA trials showed clinically meaningful reductions in apnea-hypopnea index. For patients with concurrent obesity and OSA, this expanded indication may support Zepbound from both a clinical and insurance coverage standpoint.

PCOS

None of these three medications is FDA-approved specifically for polycystic ovary syndrome. Evidence in PCOS is still emerging, and no comparative trial establishes any of the three as superior for PCOS care. Patients with PCOS and obesity should discuss treatment selection with an endocrinologist or reproductive endocrinologist familiar with the current evidence.

Do You Still Need Lifestyle Changes?

Yes. All three pivotal trials enrolled participants who received structured dietary and physical activity counseling alongside medication. The weight-loss numbers attributed to the medications are the difference over placebo — and the placebo groups were also making lifestyle changes. The medications amplify the effects of lifestyle intervention; they do not replace it.

Nutrition while on these medications: Prioritize adequate protein and hydration to preserve muscle mass during weight loss. Resistance training 2–3 times per week alongside cardiovascular activity reduces lean mass loss — particularly important when weight loss is rapid. Work with a registered dietitian or treating clinician to individualize nutrition goals; they can help determine appropriate protein targets, meal timing, and strategies to manage GI side effects during titration.

Who Should Not Take These Medications Without Extensive Medical Evaluation

Beyond the shared contraindications described above:

• History of eating disorders: Appetite suppression and caloric restriction can complicate recovery. These medications should only be used under close psychiatric and medical co-management in this population.
• Renal impairment: GI side effects can cause dehydration and worsen kidney function, particularly during dose escalation. Renal function monitoring is warranted.
• Hepatic impairment: For Wegovy injection/tablets, pharmacokinetic data does not show meaningful differences with hepatic impairment; for Saxenda, use in hepatic impairment is flagged in labeling as an area requiring caution.
• Suicidal ideation (Zepbound-specific): As noted above, Zepbound's current labeling retains a warning to monitor for depression or suicidal thoughts. Wegovy and Saxenda removed this warning in February 2026.
• Patients on glucose-lowering agents: Drug interactions with insulin and sulfonylureas require careful monitoring for hypoglycemia in all three.
• Planned pregnancy: Discontinue Wegovy at least 2 months before a planned pregnancy (long half-life washout). Discuss timing with your provider for Zepbound and Saxenda as well.

How to Choose: Decision Framework

Start with your clinical profile:

• Established cardiovascular disease (prior MI, stroke, PAD) with overweight/obesity → Wegovy's SELECT data is uniquely compelling; only drug with CV FDA indication
• Type 2 diabetes needing both weight loss and HbA1c reduction → Tirzepatide (Zepbound/Mounjaro) is commonly preferred
• Obstructive sleep apnea with obesity → Zepbound has the specific FDA indication
• Age under 18 → Wegovy injection or Saxenda only
• Prefer not to inject → Wegovy tablets (adults only)
• History of MTC or MEN2 → None of the three; discuss alternatives

Then consider access:

• What does your insurance cover?
• What are your out-of-pocket costs under each scenario?
• Is the medication available at your pharmacy?

Then weigh practical factors:

• Daily (Saxenda) vs. weekly injection (Wegovy/Zepbound) vs. daily oral (Wegovy tablet)?
• How do you weigh maximum efficacy vs. proven cardiovascular data?
• What does your provider recommend based on your specific history?

Questions to Ask Your Healthcare Provider

1. Based on my full medical history, which of these medications do you recommend, and why?
2. Which is most likely to be covered by my insurance — and is there a coverage pathway under a specific indication?
3. What side effects should I watch for in the first few weeks?
4. How will you assess whether the medication is working — and what's the timeline?
5. What do we do if my response is inadequate at 12–16 weeks?
6. How long do you anticipate I'll need to stay on this medication?
7. What happens physiologically if I stop — and how do we plan for that?
8. Are there any interactions with my current medications?
9. If I'm considering a pregnancy in the next year, how does that affect our treatment plan?
10. If my insurance covers Wegovy for cardiovascular risk reduction but not for weight loss, am I eligible for that pathway?

Availability and Prescription Access

How to Get a Prescription

All three require a prescription from a licensed healthcare provider. Options include primary care physicians, obesity medicine specialists, endocrinologists, and licensed telehealth providers. In-person evaluation allows physical examination and comprehensive assessment; telehealth offers convenience. For complex cases or prior medication failures, a specialist in obesity medicine or endocrinology typically offers the most tailored guidance.

Availability

Availability varies by dose, presentation, and pharmacy location. Novo Nordisk has stated that all Wegovy injection dose strengths are shipping regularly, but local pharmacy stock gaps can occur. Zepbound availability also varies by dose and presentation. Confirm stock with your pharmacy before your provider sends a prescription for a specific product and dose.

Frequently Asked Questions

Is Zepbound better than Wegovy for weight loss?

On population averages from pivotal clinical trials, yes — tirzepatide (Zepbound) produced higher average weight loss than semaglutide (Wegovy) at maximum doses. However, these are separate trials with different populations, so direct comparison is imprecise. Individual responses vary considerably. For patients with established cardiovascular disease, Wegovy's SELECT trial data provides a meaningful clinical advantage that may outweigh the average efficacy difference.

Is Saxenda less effective than Wegovy?

Yes, by a significant margin in clinical trials. Average weight loss with liraglutide (Saxenda) is approximately 8% versus 14.9% with semaglutide (Wegovy) injection in comparable populations. Saxenda may still be appropriate in specific access, tolerability, or insurance contexts.

Which medication has fewer side effects?

All three have similar side effect profiles dominated by gastrointestinal symptoms, particularly during dose escalation. Individual tolerability varies widely — some patients tolerate one drug far better than another for reasons that are not fully predictable. There is no clear winner across all patients.

Are these medications only injections, or is there an oral option?

Zepbound and Saxenda are injections only. Wegovy is now available as both a once-weekly injection and a once-daily oral tablet for adults. Wegovy tablets are not approved for pediatric patients. There is no approved oral version of liraglutide or tirzepatide for weight management as of this writing. Learn how to get the Wegovy pill online →

How quickly do these medications start working?

Most patients notice reduced appetite within the first 2–4 weeks at starter doses. Measurable weight loss typically begins in the first month. Efficacy continues to progress through the full titration period and beyond; most pivotal trials ran for 56–72 weeks.

Can you switch from one medication to another?

Switching between medications is common. The specific starting dose, titration approach, and any washout period depend on the current drug, current dose, reason for switching, and your provider's judgment. Discuss any switch with your prescriber rather than making changes independently.

Is Wegovy covered by Medicare?

Historically, Medicare Part D has not covered drugs used solely for weight loss. However, because Wegovy now has an FDA-approved indication to reduce cardiovascular events in eligible patients, Medicare Part D may cover it when prescribed for that cardiovascular indication. This does not apply to Saxenda or Zepbound, which lack equivalent CV indications. Coverage also depends on specific plan formularies. Confirm your plan's coverage with your insurer.

Do you gain the weight back after stopping?

For most patients, a significant portion of lost weight returns after discontinuation. STEP 4 data showed approximately two-thirds of lost weight regained within one year of stopping semaglutide. These medications are designed for long-term use in treating a chronic condition — discuss a long-term plan with your provider before starting.

What is the safest of the three medications?

All three have passed the FDA's approval process and are considered safe when used as indicated under medical supervision. "Safest" depends on your individual health profile. The risk-benefit calculation is personal and should be made with your provider. Saxenda has the longest real-world track record (approved 2014); Zepbound has the most limited long-term data (approved 2023). There are no unique safety signals for any of the three that make it universally safer than the others.

Bottom Line

Zepbound (tirzepatide) generally produces the greatest average weight loss in pivotal trials, driven by its dual GLP-1/GIP mechanism. It does not have an FDA cardiovascular-event-reduction indication as of March 17, 2026. Its self-pay pricing and presentation options have improved access.

Wegovy (semaglutide) has the most comprehensive evidence base for weight management, the only FDA-approved cardiovascular risk-reduction indication among the three, and is now available to adults as either a weekly injection or a daily oral tablet. For patients with established CVD and overweight or obesity, it is the most regulatory-supported choice as of this writing. The CV indication also opens a Medicare Part D coverage pathway that the others do not.

Saxenda (liraglutide) remains a valid option in specific access, age, or tolerability scenarios, but it generally produces substantially less average weight loss than the other two and requires daily injection. For most patients where all three are accessible, it is typically considered a second-line agent.

The best weight-loss medication is the one your healthcare provider recommends based on your complete medical history, that you can access and afford, and that you can tolerate and continue long enough to produce durable results.

Sources

This article was written and updated using the following sources. Prescribing information was accessed March 17, 2026.

1. Wegovy (semaglutide) U.S. Prescribing Information, Revised February 2026. FDA Access Data NDA 215256s033
2. Zepbound (tirzepatide) U.S. Prescribing Information, Revised January 2026. FDA Access Data NDA 217806s002
3. Saxenda (liraglutide) U.S. Prescribing Information, Revised February 2026. FDA Access Data NDA 206321s025
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384(11):989-1002.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387(3):205-216.
6. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity). NEJM. 2015;373(1):11-22.
7. Ryan DH et al. Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT). NEJM. 2024;390(13):1209-1221.
8. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
9. Wadden TA et al. (STEP 4). JAMA. 2021;325(14):1403-1413.
10. Zepbound OSA approval: FDA Press Release, June 2024
11. KFF Health Policy: A New Use for Wegovy Opens the Door to Medicare Coverage for Millions
12. FDA GLP-1 compounding safety communications: FDA Clarifies Policies for Compounders